Key result
Genetic and nongenetic biomarkers hold promise in advancing decision-making algorithms to assist diagnosis and predict disease course and therapy response in multiple sclerosis patients.
Genetic and nongenetic biomarkers hold promise for advancing personalized management and predicting disease course and therapy response in multiple sclerosis.
Multiple sclerosis (MS) is a heterogeneous disease in which diverse genetic, pathological and clinical backgrounds lead to variable therapy response. Accordingly, MS care should be tailored to address disease traits unique to each person. At the core of personalized management is the emergence of new knowledge, enabling optimized treatment and disease-modifying therapies. This overview analyzes the promise of genetic and nongenetic biomarkers in advancing decision-making algorithms to assist diagnosis or in predicting the disease course and therapy response in any given MS patient.
No takes yet. Share an insight, caveat, or question.
Pravica et al. (2013) conducted a review in Multiple sclerosis. Genetic and nongenetic biomarkers was evaluated. Genetic and nongenetic biomarkers hold promise in advancing decision-making algorithms to assist diagnosis and predict disease course and therapy response in multiple sclerosis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: